JP2016520302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520302A5 JP2016520302A5 JP2016509111A JP2016509111A JP2016520302A5 JP 2016520302 A5 JP2016520302 A5 JP 2016520302A5 JP 2016509111 A JP2016509111 A JP 2016509111A JP 2016509111 A JP2016509111 A JP 2016509111A JP 2016520302 A5 JP2016520302 A5 JP 2016520302A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- receptor
- polynucleotide
- tgfβ
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 24
- 108091033319 polynucleotide Proteins 0.000 claims 17
- 102000040430 polynucleotide Human genes 0.000 claims 17
- 239000002157 polynucleotide Substances 0.000 claims 17
- 108091005735 TGF-beta receptors Proteins 0.000 claims 16
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 9
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 108091008874 T cell receptors Proteins 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- -1 ErbB3 / 4 Chemical compound 0.000 claims 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 5
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims 4
- 108010060889 Toll-like receptor 1 Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 3
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 3
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 3
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 3
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 3
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 3
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 3
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 2
- 102100038083 Endosialin Human genes 0.000 claims 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 101710088083 Glomulin Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101001076732 Homo sapiens RNA-binding protein 27 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102000004553 Interleukin-11 Receptors Human genes 0.000 claims 2
- 108010017521 Interleukin-11 Receptors Proteins 0.000 claims 2
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims 2
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims 2
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 102100025873 RNA-binding protein 27 Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 claims 1
- 206010062767 Hypophysitis Diseases 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 210000001015 abdomen Anatomy 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003635 pituitary gland Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000009258 tissue cross reactivity Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361812917P | 2013-04-17 | 2013-04-17 | |
| US61/812,917 | 2013-04-17 | ||
| PCT/US2014/034570 WO2014172584A1 (en) | 2013-04-17 | 2014-04-17 | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520302A JP2016520302A (ja) | 2016-07-14 |
| JP2016520302A5 true JP2016520302A5 (OSRAM) | 2017-05-25 |
| JP6578271B2 JP6578271B2 (ja) | 2019-09-18 |
Family
ID=50877664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509111A Active JP6578271B2 (ja) | 2013-04-17 | 2014-04-17 | 免疫抑制ＴＧＦ−βシグナルコンバーター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10584158B2 (OSRAM) |
| EP (2) | EP2986636B1 (OSRAM) |
| JP (1) | JP6578271B2 (OSRAM) |
| CN (1) | CN105452287A (OSRAM) |
| CA (1) | CA2909701C (OSRAM) |
| WO (1) | WO2014172584A1 (OSRAM) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| EP2986636B1 (en) * | 2013-04-17 | 2018-11-14 | Baylor College Of Medicine | Immunosuppressive tgf-beta signal converter |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| MA41538A (fr) * | 2014-10-17 | 2017-12-26 | Baylor College Medicine | Cellules immunitaires bipartites et tripartites de signalisation |
| GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
| SI3240805T1 (sl) | 2014-12-15 | 2025-04-30 | The Regents Of The University Of California | Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20 |
| US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
| CA2975147C (en) | 2015-01-31 | 2025-06-10 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS OF ADMINISTRATION OF THERAPEUTIC MOLECULES TO T CELLS |
| US20160228547A1 (en) * | 2015-02-06 | 2016-08-11 | Batu Biologics, Inc. | Chimeric antigen receptor targeting of tumor endothelium |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US20180044404A1 (en) | 2015-03-05 | 2018-02-15 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| RU2706582C2 (ru) | 2015-04-13 | 2019-11-19 | Пфайзер Инк. | Химерные антигенные рецепторы, нацеленные на антиген созревания B-клеток |
| US10857181B2 (en) | 2015-04-21 | 2020-12-08 | Enlivex Therapeutics Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| EP3331550B1 (en) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
| AU2015376656B2 (en) * | 2015-08-07 | 2018-01-04 | Shenzhen In Vivo Biomedicine Technology Limited Company | Chimeric antigen receptor containing a Toll-like receptor intracellular domain |
| SMT202300027T1 (it) * | 2015-10-30 | 2023-05-12 | Univ California | Polipeptidi sensibili al fattore di crescita trasformante beta e le loro modalità d’uso |
| US11648268B2 (en) | 2015-12-09 | 2023-05-16 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| CA3014885A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN109311984A (zh) * | 2016-03-11 | 2019-02-05 | 蓝鸟生物公司 | 基因组编辑的免疫效应细胞 |
| EP3439698A1 (en) * | 2016-04-05 | 2019-02-13 | GlaxoSmithKline Intellectual Property Development Ltd | Inhibition of tgfbeta in immunotherapy |
| SG11201808831TA (en) | 2016-04-15 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| CA3021455A1 (en) * | 2016-04-20 | 2017-10-26 | Fred Hutchinson Cancer Research Center | Immunomodulatory il2r fusion proteins and uses thereof |
| KR20230167769A (ko) * | 2016-08-26 | 2023-12-11 | 베이롤 칼리지 오브 메드신 | 세포 치료요법을 위한 항상성 활성 사이토킨 수용체 |
| AU2017319151B2 (en) * | 2016-08-30 | 2024-01-11 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| CN110050066A (zh) * | 2016-10-17 | 2019-07-23 | 蓝鸟生物公司 | TGFβR2核酸内切酶变体、组合物和使用方法 |
| DK3541833T5 (da) | 2016-11-17 | 2024-09-02 | 2Seventy Bio Inc | TGFß signalkonverter |
| AU2018236461B2 (en) | 2017-03-17 | 2025-03-27 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| SI3628049T1 (sl) | 2017-05-04 | 2023-10-30 | Acceleron Pharma Inc. | Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba |
| CN108853144A (zh) * | 2017-05-16 | 2018-11-23 | 科济生物医药（上海）有限公司 | Toll样受体激动剂与免疫效应细胞的联用 |
| KR102412805B1 (ko) * | 2017-05-31 | 2022-06-27 | 크라제 메디컬 씨오 리미티드 | 세포 면역 요법을 위한 조성물 및 방법 |
| CN107236762A (zh) * | 2017-06-19 | 2017-10-10 | 河北浓孚雨生物科技有限公司 | 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法 |
| CN109880803B (zh) * | 2017-12-06 | 2024-06-07 | 恺兴生命科技(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019173324A1 (en) * | 2018-03-06 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| TWI823906B (zh) | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| US20210221864A1 (en) * | 2018-08-24 | 2021-07-22 | City Of Hope | Masked cytokine conjugates |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| WO2020186219A1 (en) * | 2019-03-14 | 2020-09-17 | The Regents Of The University Of California | Pooled knock-in screening and heterologous polypeptides co-expressed under the control of endogenous loci |
| US20220289824A1 (en) * | 2019-08-15 | 2022-09-15 | Nantbio, Inc. | TGF-beta TRAP |
| JP2022545167A (ja) * | 2019-08-30 | 2022-10-26 | アロジーン セラピューティクス，インコーポレイテッド | Ｔｇｆベータ結合ドメインを含むキメラサイトカイン受容体 |
| US20230030680A1 (en) * | 2020-01-07 | 2023-02-02 | St. Jude Children's Research Hospital, Inc | Chimeric gmcsf-il18 receptor |
| CN113150167A (zh) * | 2020-01-22 | 2021-07-23 | 中国人民解放军总医院第五医学中心 | 一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计 |
| CN115698038A (zh) * | 2020-06-01 | 2023-02-03 | 上海君赛生物科技有限公司 | 信号转换受体及其用途 |
| US20230310606A1 (en) * | 2020-07-17 | 2023-10-05 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| CN112210543B (zh) * | 2020-07-30 | 2023-01-03 | 山东省成体细胞产业技术研究院有限公司 | 一种针对实体瘤克服TGF-β免疫抑制的CAR-T细胞 |
| US20230398216A1 (en) * | 2020-10-22 | 2023-12-14 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
| US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
| KR20230132806A (ko) * | 2021-01-15 | 2023-09-18 | 고쿠리츠 다이가쿠 호우징 도우카이 고쿠리츠 다이가쿠 기코우 | 키메라 표적 인자 수용체 |
| CN114540311A (zh) * | 2022-02-24 | 2022-05-27 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其应用 |
| CN114525260A (zh) * | 2022-02-24 | 2022-05-24 | 深圳市先康达生命科学有限公司 | 一种同时表达融合蛋白及嵌合抗原受体的免疫细胞及其应用 |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| CN120981484A (zh) | 2023-01-23 | 2025-11-18 | 汉诺威医学院 | 抗entpd3嵌合抗原受体 |
| KR20250165594A (ko) | 2023-02-07 | 2025-11-26 | 퀠 테라퓨틱스 리미티드 | Treg 세포의 배양 방법 |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| EP4509522A1 (en) | 2023-08-16 | 2025-02-19 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| CA2719767A1 (en) | 2008-03-27 | 2009-10-01 | Burnham Institute For Medical Research | Inhibitors of antigen receptor-induced nf-.kappa.b activation |
| EP3467101A3 (en) * | 2010-09-08 | 2019-06-19 | Baylor College of Medicine | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells |
| ES2649967T3 (es) * | 2011-04-08 | 2018-01-16 | Baylor College Of Medicine | Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas |
| ES2888651T3 (es) * | 2011-07-29 | 2022-01-05 | Univ Pennsylvania | Receptores de conmutación coestimulantes |
| EP2986636B1 (en) * | 2013-04-17 | 2018-11-14 | Baylor College Of Medicine | Immunosuppressive tgf-beta signal converter |
-
2014
- 2014-04-17 EP EP14727664.6A patent/EP2986636B1/en active Active
- 2014-04-17 WO PCT/US2014/034570 patent/WO2014172584A1/en not_active Ceased
- 2014-04-17 CA CA2909701A patent/CA2909701C/en active Active
- 2014-04-17 US US14/785,248 patent/US10584158B2/en active Active
- 2014-04-17 CN CN201480034691.5A patent/CN105452287A/zh active Pending
- 2014-04-17 EP EP18198300.8A patent/EP3470423B1/en active Active
- 2014-04-17 JP JP2016509111A patent/JP6578271B2/ja active Active
-
2020
- 2020-01-15 US US16/743,987 patent/US20200140520A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520302A5 (OSRAM) | ||
| JP2016513458A5 (OSRAM) | ||
| Patel et al. | From concept to cure: The evolution of CAR-T cell therapy | |
| JP2014512183A5 (OSRAM) | ||
| RU2015116901A (ru) | Композиции и способы для имуннотерапии | |
| Le et al. | Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective | |
| Li et al. | Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice | |
| JP2015535689A5 (OSRAM) | ||
| JP2017531687A5 (OSRAM) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| JP2017503472A5 (OSRAM) | ||
| BR112017008972A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra carcinoma hepatocelular (hcc) e outros cânceres | |
| PH12019500750A1 (en) | Chimeric antigen receptors for the treatment of cancer | |
| CR20180074A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer | |
| PE20190124A1 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer | |
| MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
| JP2018526453A5 (OSRAM) | ||
| JP2015509716A5 (OSRAM) | ||
| PE20181075A1 (es) | Nuevos pepticos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia linfocitica cronica (llc) y otros tipos de cancer | |
| RU2018116565A (ru) | Терапевтические соединения и способы | |
| JP2017513470A5 (OSRAM) | ||
| Schmidt et al. | A killer choice for cancer immunotherapy | |
| WO2020092736A8 (en) | Methods and materials for treating cancer | |
| Guinn et al. | Recent advances and current challenges in tumor immunology and immunotherapy | |
| JP2018100243A5 (OSRAM) |